Literature DB >> 8576342

Performance of a rapid, on-site human immunodeficiency virus antibody assay in a public health setting.

W J Kassler1, C Haley, W K Jones, A R Gerber, E J Kennedy, J R George.   

Abstract

Rapid, on-site human immunodeficiency virus (HIV) testing has the potential to improve the delivery of prevention services in publicly funded counseling and testing sites. The Single Use Diagnostic System (SUDS) HIV-1 is the only rapid enzyme immunoassay (EIA) approved for diagnostic use in the United States. To evaluate the feasibility of using SUDS in public clinics and to validate the test's performance in a public health laboratory, we conducted blinded SUDS testing on plasma sent for HIV testing. From 19 March through 30 June 1993, 1,923 consecutive samples from a sexually transmitted diseases clinic and an HIV counseling and testing clinic were tested on site with SUDS. Tests done in the first two weeks with a malfunctioning centrifuge n = 402) and those done when there were excessively high temperatures in the laboratory (n = 53) were analyzed separately. Of 1,466 tests, 39 were positive by both SUDS and EIA (with Western blot [immunoblot] confirmation) and 7 were SUDS positive and EIA negative. Western blotting was used as the "gold standard" to adjudicate these discrepancies. There were no SUDS-negative and EIA-positive tests. Compared with that of EIA (with Western blot confirmation), the sensitivity of SUDS was 100% (95% confidence interval, 88.8 to 100%) and the specificity was 99.5% (95% confidence interval, 98.9 to 99.8%). The positive predictive value of SUDS was 88% in the STD clinic and 81% in the HIV counseling and testing clinic. There was a 7.7-fold increase in false positives, from 0.48 to 3.7%, when there was inadequate centrifugation and when the temperature exceeded the manufacturer's recommendations. Rapid, on-site HIV testing by the SUDS assay is feasible and practical in public health settings. The test can be performed accurately, at reasonable cost, and within the time frame of a typical clinic visit. Caution should be used, however, as two conditions adversely affected the accuracy of this test: inadequate specimen preparation and elevated temperature.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576342      PMCID: PMC228603          DOI: 10.1128/jcm.33.11.2899-2902.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Evaluation of United States-licensed human immunodeficiency virus immunoassays for detection of group M viral variants.

Authors:  W H Koch; P S Sullivan; C Roberts; K Francis; R Downing; T D Mastro; J Nkengasong; D Hu; S Masciotra; C Schable; R B Lal
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  Comparison of murex single-use diagnostic system with traditional enzyme immunoassay for detection of exposure to human immunodeficiency virus.

Authors:  Christin A Martin; David F Keren
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

3.  Point-of-care testing for HIV: HIV counselling and testing.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis       Date:  2002-03

4.  Performance of a rapid, on-site human immunodeficiency virus antibody assay in public health settings.

Authors:  S C Arya
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

5.  Performance characteristics of a rapid new immunochromatographic test for detection of antibodies to human immunodeficiency virus.

Authors:  Rodrigo Ribeiro-Rodrigues; Lauro Ferreira da Silva Pinto Neto; Carla B Cunha; Valéria P Cabral; Reynaldo Dietze
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

Review 6.  Diagnostic point-of-care tests in resource-limited settings.

Authors:  Paul K Drain; Emily P Hyle; Farzad Noubary; Kenneth A Freedberg; Douglas Wilson; William R Bishai; William Rodriguez; Ingrid V Bassett
Journal:  Lancet Infect Dis       Date:  2013-12-10       Impact factor: 25.071

7.  Diagnosis of human immunodeficiency virus type 1 infection with different subtypes using rapid tests.

Authors:  S Phillips; T C Granade; C P Pau; D Candal; D J Hu; B S Parekh
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

8.  Field evaluation of the Determine rapid human immunodeficiency virus diagnostic test in Honduras and the Dominican Republic.

Authors:  C J Palmer; J M Dubon; E Koenig; E Perez; A Ager; D Jayaweera; R R Cuadrado; A Rivera; A Rubido; D A Palmer
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

9.  Alternative HIV testing methods among populations at high risk for HIV infection.

Authors:  Dawn R Greensides; Ruth Berkelman; Amy Lansky; Patrick S Sullivan
Journal:  Public Health Rep       Date:  2003 Nov-Dec       Impact factor: 2.792

10.  Evaluation and treatment of the human immunodeficiency virus-1-exposed infant.

Authors: 
Journal:  Paediatr Child Health       Date:  2004-07       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.